This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Bono, J. S. Articles by LoBuglio, A. F. Search for Related Content PubMed PubMed Citation Articles by de Bono, J. S. Articles by LoBuglio, A. F.

ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas

¹ Institute For Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; ² Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama; and ³ XOMA (US) LLC, Berkeley, California

Purpose: To determine the feasibility of administration, safety, toxicity, immunogenicity, pharmacokinetics, maximum tolerated dose, and biodistribution of ING-1, a high-affinity, Human-Engineered monoclonal antibody (heMAb) to the M_r 40,000 epithelial cell adhesion molecule Ep-CAM, in patients with advanced adenocarcinomas.

Experimental Design: ING-1 was initially administered to patients as a 1-hour intravenous infusion every 3 weeks. Toxicity and pharmacokinetic data led to the evaluation of a weekly schedule. The distribution of iodine-131 (¹³¹I)-labeled ING-1 was studied.

Results: Twenty-five patients received 82 courses of ING-1. Minimal toxicity was initially observed at the 0.03-, 0.10-, and 0.30-mg/kg dose levels. A patient dosed at 1.0 mg/kg developed acute pancreatitis with severe abdominal pain, nausea, and vomiting. A patient dosed at 0.3 mg/kg had an asymptomatic amylase and lipase elevation to 502 units/L and 1,627 units/L, respectively. Both patients made uncomplicated recoveries. No other dose-limiting toxicities were observed. Regardless of dose, the volume of distribution (mean ± SEM) was 46.6 ± 1.6 mL/kg. ING-1 clearance decreased with increasing dose. To minimize toxicity and increase dose intensity, we then administered ING-1 weekly. No significant toxicity was observed in 7 patients dosed at 0.1 mg/kg. Studies of ¹³¹I-labeled ING-1 biodistribution showed radiolocalization to colorectal and prostate cancers. A patient with colorectal cancer had an 80% decrement in the levels of carcinoembryonic antigen.

Conclusion: The recommended dose for ING-1 is 0.10 mg/kg by intravenous infusion weekly. The absence of severe toxicity at this dose, low immunogenicity, and preliminary evidence of ING-1 tumor localization and antitumor efficacy support the further clinical development of this antibody to treat Ep-CAM–positive malignant diseases.

This article has been cited by other articles:

				M. Amann, K. Brischwein, P. Lutterbuese, L. Parr, L. Petersen, G. Lorenczewski, E. Krinner, S. Bruckmeier, S. Lippold, R. Kischel, et al. Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3 Cancer Res., January 1, 2008; 68(1): 143 - 151. [Abstract] [Full Text] [PDF]

				D Fong, M Steurer, P Obrist, V Barbieri, R Margreiter, A Amberger, K Laimer, G Gastl, A Tzankov, and G Spizzo Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance J. Clin. Pathol., January 1, 2008; 61(1): 31 - 35. [Abstract] [Full Text] [PDF]

				S. Goel, R. J. Bauer, K. Desai, A. Bulgaru, T. Iqbal, B.-K. Strachan, G. Kim, A. Kaubisch, G. F. Vanhove, G. Goldberg, et al. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors Ann. Onc., October 1, 2007; 18(10): 1704 - 1707. [Abstract] [Full Text] [PDF]

				J. G. W. Kosterink, P. M. J. McLaughlin, M. N. Lub-de Hooge, H. H. Hendrikse, J. van Zanten, E. van Garderen, M. C. Harmsen, and L. F. M. H. de Leij Biodistribution Studies of Epithelial Cell Adhesion Molecule (EpCAM)-Directed Monoclonal Antibodies in the EpCAM-Transgenic Mouse Tumor Model J. Immunol., July 15, 2007; 179(2): 1362 - 1368. [Abstract] [Full Text] [PDF]